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Summary 
 
The incidence of malaria in sub-Saharan Africa is falling and in many countries on the 
continent the pattern of malaria infection within the country is becoming more 
heterogeneous. National malaria control programmes need to take this into account and the 
‘one size fits all’ approach to malaria control may no longer be appropriate, with individual 
approaches being needed in different parts of a country. This applies particularly to decisions 
on the introduction of new control tools. Recent experience with Seasonal Malaria 
Chemoprevention and with the RTS,S/AS01 malaria vaccine provides examples of 
interventions  which need to be deployed  on a restricted rather than a national basis, taking 
account  of differences in  climate  and the intensity of malaria infection between regions 
within a country. Designing, implementing and monitoring more complex national malaria 
control programmes will require staff skilled in many disciplines, and substantial funding will 
be needed to sustain these more complex control programmes, even though the burden of the 
disease is falling.   
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Introduction 
 
Measuring the burden of malaria is challenging as the clinical features of the infection are 
non-specific and mimicked by many other infectious diseases and many deaths from malaria 
occur at home without prior investigation. However, there is a consensus that during the past 
15 years both the number of cases of malaria and the number deaths from malaria has fallen 
by about a half, despite a substantial increase in the population of malaria endemic areas 
during this period.1 This success has been achieved primarily through scaling up of 
established interventions - insecticide treated bednets (ITNs), indoor residual spraying (IRS) 
and artemisinin combination therapy (ACT). Modelling suggests that the most important of 
these interventions has been the widespread deployment of ITNs; it is estimated that about a 
half of the population at risk for malaria now sleeps under an ITN, and that approximately 
70% of the reduction in burden between 2000 and 2015 can be attributed to deployment of 
this intervention.2   
 
Recent achievements in malaria control are a cause for celebration but the fact remains that in 
2015 there were still an estimated 212 [range 148-304] million cases of malaria and 429 
[range 235-639] thousand preventable deaths from malaria, a large majority of the latter 
occurring in African children.1 Further reductions in the malaria burden could be achieved 
through scaling up of currently employed control tools, especially in areas where coverage 
remains low, and this is a priority. However, in areas where good coverage has been achieved 
already, this is likely to become increasingly difficult and expensive as it will be necessary to 
reach populations that are difficult to access and to persuade those resistant to control 
measures, such as the use of ITNs, to adopt them. Furthermore, both the efficacy of ITNs and 
of ACTs are threatened by the emergence and spread of resistance to pyrethroid insecticides 
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in Africa3  and  of artemisinin resistance in southeast Asia.4 Thus, new control tools are 
needed as an additional measure in areas where current control methods, correctly applied, 
are not achieving full control of the infection, to replace the insecticides and drugs currently 
in use if resistance renders them ineffective and finally to contribute to elimination of the 
infection. Some of the control tools not widely in use that are currently available, or may 
become so in the near to medium term future, are shown in Table 1.  
 
Deciding on the optimal use of additional malaria control tools 
 
Development of ACTs was an enormous advance because, at the time that they were 
introduced, they were highly effective against blood stage infections of all five human 
malaria parasite species across the malaria endemic world and there was no known resistance. 
Similarly, when first introduced, ITNs were highly effective in nearly all highly malaria 
endemic areas where the vector mosquitoes feed predominantly at night.  Consequently, at 
this time, national policies for malaria control could be developed which were simple to 
follow and could be implemented across a country without a need to take into account 
regional differences in the epidemiology of the infection.  This situation no longer applies in 
many countries so that the additional methods of malaria control becoming available will 
need to be deployed in a more focused manner to achieve their maximum impact, taking into 
account a number of variables such as the seasonality of malaria, its intensity and preferences 
of the population for specific control measures in different parts of a country. Two recent 
examples of how a rational, focused approach to the deployment of two new malaria control 
interventions has been developed or is being considered are described in the following two 
sections of the paper. 
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Seasonal malaria chemoprevention 
 
In many parts of sub-Saharan Africa, malaria transmission is highly seasonal (Figure 1). 
There are few data on the incidence of clinical episodes of malaria by month of year in sub-
Saharan Africa but using monthly rainfall as a surrogate for malaria transmission  allowed 
production of a map of the areas where malaria transmission is likely to be highly seasonal.5 
These areas are found mostly in the Sahel and sub-Sahel region of Africa, although there are 
also areas with seasonal transmission in southern and eastern Africa. However, in most of the 
latter areas, the incidence of the infection is low. In contrast, in the areas of the Sahel and 
sub-Sahel where transmission is highly seasonal, the incidence of malaria remains very high, 
despite widespread deployment of current control measures.  The population of these areas is 
in the region of 200-300 million, approximately a third of the population of sub-Saharan 
Africa.   
 
Chemoprevention of different kinds has been used for the prevention of malaria in the 
endemic population of countries in Africa on many occasions during the past century but it 
has rarely been implemented on any scale because of concerns over the difficulty of 
achieving a high level of coverage, cost, the risk of enhancing drug resistance and a potential 
to impair the development of naturally acquired immunity.  Several of these drawbacks 
would be diminished if antimalarials were given for a limited period rather than throughout 
the year. This consideration led to the concept of Seasonal Malaria Chemoprevention (SMC) 
(previously called Intermittent Preventive Treatment in children [IPTc]), an intervention in 
which young children  resident in areas where malaria transmission is highly seasonal are 
given  a full  course of an effective antimalarial combination at monthly intervals on three or 
four occasions during the peak malaria transmission season. A series of trials conducted in 
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countries of the Sahel and sub-Sahel showed that this is a highly effective intervention 
leading to 70-80% reductions in the incidence of clinical episodes of malaria and severe 
malaria and a probable reduction in deaths.6 Therefore, in 2012, WHO’s Malaria Policy 
Advisory Committee recommended the implementation of SMC for children under the age of 
five years using sulphadoxine/pyrimethamine (SP) plus amodiaquine (AQ) in countries of the 
Sahel and sub-Sahel where malaria transmission is highly seasonal.  With support from 
UNITAID to the ACCESS SMC programme,7 and financial support from other donors, SMC 
is now being widely disseminated across countries of the Sahel and it is estimated that around 
18 million children will have received SMC in 2016. 
 
Many countries of West Africa span areas of savannah, where malaria transmission of 
malaria is highly seasonal, and forest areas where it is not. Thus, these countries have had to 
develop a regional national malaria control programme in which some areas of the country 
receive the added intervention of SMC whilst others do not. It was initially considered that 
implementation of such a policy might prove to be politically sensitive but this has not 
proved to be the case. The principle of implementing regionally different malaria control 
policies within the same country has thus been established firmly. The SMC experience has 
been important in showing that national malaria control programmes can establish different 
malaria control programmes in different regions of the same country based on a sound 
knowledge of the epidemiology of the infection, with success and without political 
interference.   
 
The RTS,S/AS01 malaria vaccine  
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Development of the RTS,S/AS01 malaria vaccine, the first malaria vaccine to obtain approval 
from a major regulatory authority (the European Medicines Agency) has taken 30 years. 
Results from a large phase 3 trial conducted in 11 centres in 7 countries in sub-Saharan 
Africa showed that three doses of vaccine given to children aged 5-17 months followed by a 
booster dose 18 months later gave an efficacy of 36% against clinical attacks of malaria 
during a four year period of follow-up.8 The vaccine was less effective when given with 
routine Expanded Programme of Immunisation (EPI) vaccine at the ages of 6-14 weeks.8  An 
unexplained increase in meningitis was observed in older, but not in younger children who 
received the vaccine and there was a suggestion that the proportion of cases of severe malaria 
due to cerebral malaria was increased, although the overall incidence of severe malaria was 
reduced in vaccinated children.  For these reasons, and because of concerns about the 
practicability of giving a fourth dose, WHO’s SAGE committee did not recommend 
immediate deployment of the vaccine on a large scale but the conduct of 3-5 large scale pilot 
implementation studies.9 Funding to support three large pilot studies has now been obtained 
and these are being planned. Where  the vaccine might be  be most effective if the results of 
the pilot studies suggest that it should be deployed more generally requires careful 
consideration. 
 
The efficacy of RTS,S/AS01 in preventing clinical malaria showed  some variation between 
study sites but  the vaccine was effective across all sites, independent of the level of malaria 
transmission at that site. This was an important finding because the potential public health 
importance of the vaccine depends not only upon its efficacy but primarily upon the number 
of cases of malaria it would prevent in a  particular epidemiological situation, and hence the 
potential financial savings to the health system that might follow from its deployment. 
Analysis of the results of the phase 3 trial by site showed that at Kilifi, Kenya, the site with 
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the lowest level of transmission, administration of the vaccine to 1,000 children would save  
approximately 200 cases over a four year period whilst in another area of Kenya (Siaya), 
vaccination of 1,000 children would save over 6000 cases  (Figure 2)8.  The implications of 
these findings for the Kenyan Ministry of Health are obvious. If the Ministry decides to 
deploy the vaccine in the country following the pilot studies, then a regional policy will be 
needed in which the vaccine is deployed only in the areas with the highest level of 
transmission, such as those situated around Lake Victoria, and not in other parts of the 
country.  Other national malaria control programmes will need to make similar decisions 
based on detailed knowledge of the epidemiology of malaria in different parts of their 
country. Unless further  malaria vaccines being developed have a very high level of efficacy 
and are very cheap, similar decisions will be need to be taken about their deployment in the 
future. Experience with the RTS,S/AS01 vaccines provides an example of an intervention for 
which intensity of infection will be the major factor in determining where it could be 
deployed most effectively.   
 
Implications of a focused approach to malaria control 
 
The need for more flexible control programmes has important consequences for national 
malaria control programmes. National scale-up of ITNs and ACTs requires predominantly 
experienced logisticians and not scientists. However, the design, implementation and 
monitoring of more complex programmes based on considerations of local epidemiological, 
sociological and economic factors  requires staff well trained in a variety of disciplines 
including epidemiology, entomology, parasitology, social sciences and economics. Careful 
monitoring of new programmes will be essential so that they can be modified rapidly in the 
face of changes in the epidemiology of the infection brought about by the success of the  
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intervention or by other factors, for example a change in the peak age of cases from young to 
school-aged children.10 This will require a well-trained team of scientists. Thus, 
paradoxically, as malaria control improves and the malaria burden declines, more rather less 
well trained staff in areas such as entomology will be needed.  Achieving the funds to needed 
to sustain these experienced teams at a time when the burden of malaria is decreasing will be 
challenging but is essential if the gains made  are to be sustained and malaria to be 
eliminated.  
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Figure captions 
 
Figure 1 The seasonality of malaria episodes in Mali (unpublished data from  an on-going 
trial of the impact of adding azithromycin to the antimalarials used for SMC  in Burkina Faso 
and Mali.  
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Figure 2 The number of cases of malaria prevented over a four- year period by vaccination of 
1,000 children aged 5-17 months with the malaria vaccine RTS,S/AS01.  The different study 
sites are ranked according to the level of malaria transmission at that site, with the sites with 
the lowest level of transmission indicated on the left of the figure.  The left hand columns in 
red (R3C) refer to children who received only the first three doses of vaccine, the right hand 
columns in blue (R3R) to those who received a subsequent booster dose of vaccine. (RTS,S 
Clinical Trials Partnership. Lancet 2015; 386:31-45).     
 
Table caption 
 
Table 1 Additional malaria control interventions not currently used widely and/or under 
development which might be used in a selective way in a national malaria control 
programme.  
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Table 1 Additional malaria control interventions not currently used widely and/or under 
development which might be used in a selective way in a national malaria control 
programme.  
 
Vector control                          Chemoprevention                                Vaccination 
Larviciding                            Mass drug administration               Pre-erythrocytic vaccines 
Repellents                          Transmission blocking drugs               Blood stage vaccines 
Mosquito traps                                Ivermectin1                        Transmission blocking vaccines       
Bacterial infection                                                                                                                        
of mosquitoes 
Genetically modified                                                                                                     
mosquitoes2  
 
Notes: 1Ivermectin, used in mass drug programmes against filarial infections reduces                
             mosquito survival and hence has a malaria transmission effect. 
           2A variety of approaches to genetic modification of mosquitoes are being explored  
             including induction of resistance of the mosquito to malaria infection and production  
             of all male mosquitoes.11  
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